Qualified Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enterprise AI for health systems; raised $125M Series B (NEA + Anthropic fund, March 2026); 500K+ users; AI agents covering ~7% of US hospital revenue; integrates with existing EHR systems
About
Qualified Health is an enterprise AI company building intelligent systems for large health systems and hospital networks. Founded to address the complexity of clinical and operational decision-making in healthcare, the company develops AI agents that assist clinicians, administrators, and care teams with data-intensive workflows. Its platform is designed to integrate with existing electronic health record systems and enterprise infrastructure, enabling health systems to deploy AI without replacing legacy technology.\n\nThe company targets enterprise health systems — specifically the largest hospital networks in the United States — with AI tools that span clinical decision support, administrative automation, and patient engagement. Qualified Health emphasizes safety, compliance, and interpretability in its models, which is critical for adoption in regulated healthcare settings. The platform is built to handle the scale and data sensitivity requirements of organizations managing hundreds of thousands of patients.\n\nQualified Health raised a $125M Series B led by NEA and backed by the Anthropic fund, signaling strong confidence from both traditional healthcare investors and AI-native institutional backers. The company has grown to 500,000+ users and its platform now touches approximately 7% of total US hospital revenue — a remarkable reach for a relatively young company. As of early 2026, Qualified Health is one of the best-capitalized enterprise health AI startups in the market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.